Annual Screening Strategies in BRCA1 and BRCA2 Gene Mutation Carriers: A Comparative Effectiveness Analysis

Lee, C.H.

doi:10.1016/j.breastdis.2013.01.034

Cited by 1 publication

(3 citation statements)

References 22 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First, breast cancer in the BRCA-preDx awareness group was more often detected by imaging, mostly MRI, while in the BRCA-postDx awareness group self-palpation was most prevalent. We attribute this difference to the use of MRI in the BRCA-preDx awareness group, as suggested by international guidelines ( 7 , 14 ) and previous studies that have shown that MRI has superior sensitivity in the BRCA1/2 carrier population ( 15 , 16 ). Second, we show that more in situ pathology was found in the BRCA-preDx awareness group.…”

Section: Discussionmentioning

confidence: 90%

“…These findings are in line with the scientific background on which the current guidelines were established ( 7 ): MRI is more sensitive than mammography for women at high risk of developing breast cancer ( 17 – 19 ). The use of combined screening modalities elevates the sensitivity of the examination ( 15 , 19 ) and can lead to detection at favorable stages compared with mammography alone ( 20 ). Additionally, mammography alone has a higher false-negative rate in BRCA PVcarriers ( 21 ), in high-density breast tissue ( 21 – 23 ) and in rapidly growing aggressive tumors ( 24 , 25 ).…”

Section: Discussionmentioning

confidence: 99%

“…For example, the starting age and the age limit for high-risk screening are not well-known and based on limited observational data ( 26 , 28 ). The interval time between each screening is also not well established, and there is only partial comparative information regarding different interval durations based on age ( 15 ).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

“High-Risk Breast Cancer Screening in BRCA1/2 Carriers Leads to Early Detection and Improved Survival After a Breast Cancer Diagnosis”

et al. 2021

View full text Add to dashboard Cite

BackgroundGermline BRCA1/2 pathogenic variant (PV) carriers have high lifetime risk of developing breast cancer and therefore subjected to intense lifetime screening. However, solid data on the effectiveness of high-risk screening of the BRCA1/2 carrier population is limited.Patients and MethodsRetrospectively, we analyzed 346 women diagnosed with breast tumors. Patients were divided according to the timing of BRCA1/2 PVrecognition, before (BRCA-preDx awareness, N = 62) or after (BRCA-postDx awareness group, N = 284) cancer diagnosis.ResultsMedian follow-up times were 131.42 and 93.77 months in the BRCA-preDx awareness and BRCA-postDx awareness groups, respectively. In the BRCA-preDx awareness group, 78.7% of the patients had invasive tumors and 21.3% were diagnosed with pure ductal carcinoma in situ. In contrast, in the BRCA-postDx awareness group over 93% of women were diagnosed with invasive cancer and only 6.4% had in situ disease. The mode of tumor detection differed significantly between the groups: 71.9% in the BRCA-postDx awareness group and 26.2% in the BRCA-preDx awareness group were diagnosed after personally palpating a lump. Tumor size and nodal involvement were significantly more favorable in the BRCA-preDx awareness group. T stage was significantly lower in the BRCA-preDx awareness group: 54.84% at T1 and 20.96% at Tis. In the BRCA-postDx awareness group, only 37.54% were at T1 and 6.49% at Tis. The N stage was also significantly lower in the BRCA-preDx awareness group: 71% had no lymph node metastases, compared with 56.1% in the BRCA-postDx awareness group. Additionally, therapeutic procedures varied between the groups: BRCA-preDx awareness group patients underwent more breast conserving surgeries. Axillary lymph node dissection was done in 38% of women in the BRCA-postDx awareness group and in only 8.7% of the BRCA-preDx awareness group patients. Interestingly, improved survival was found among patients who underwent high-risk screening (hazard ratio=0.34).ConclusionsHigh-risk screening might facilitate downstaging of detected breast tumor among BRCA1/2 carrier population.

show abstract

Section: Discussionmentioning

confidence: 90%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

“High-Risk Breast Cancer Screening in BRCA1/2 Carriers Leads to Early Detection and Improved Survival After a Breast Cancer Diagnosis”

et al. 2021

View full text Add to dashboard Cite

show abstract

Annual Screening Strategies in BRCA1 and BRCA2 Gene Mutation Carriers: A Comparative Effectiveness Analysis

Abstract: Background-While breast cancer screening with mammography and MRI is recommended for BRCA mutation carriers, there is no current consensus on the optimal screening regimen.

Cited by 1 publication

References 22 publications

“High-Risk Breast Cancer Screening in BRCA1/2 Carriers Leads to Early Detection and Improved Survival After a Breast Cancer Diagnosis”

“High-Risk Breast Cancer Screening in BRCA1/2 Carriers Leads to Early Detection and Improved Survival After a Breast Cancer Diagnosis”

Contact Info

Product

Resources

About